ArticleBiomolecules2025
PFKM-Mediated Glycolysis: A Pathway for ASIC1 to Enhance Cell Survival in the Acidic Microenvironment of Liver Cancer.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The glycolytic enzyme PFKM promotes renal fibrosis by activating the NF-κB pathway via lactate-mediated H3K18 lactylation.Cellular and molecular life sciences : CMLS · 2026Article
- Targeting phosphofructokinase in cancer: integrating natural products for metabolic reprogramming and therapeutic innovation.Frontiers in pharmacology · 2026Review
- Decoding protein lactylation in the pathogenesis and progression of gynecological cancer.American journal of cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The acidic tumor microenvironment plays a critical role in promoting liver cancer cell survival by enhancing glycolysis and adaptive mechanisms. Acid-sensing ion channel 1 (ASIC1) is a key regulator of pH sensing, but its role in liver cancer progression and underlying mechanisms remain unclear. In this study, we examined ASIC1 expression in clinical liver tumor tissues using immunohistochemistry and immunofluorescence, correlating it with tumor stages. HepG2 and Li-7 cells were cultured in tumor supernatant and acidic conditions to mimic the tumor microenvironment. Western blotting assessed the expression of ASIC1 and glycolysis-related enzymes, with siRNA transfections used to investigate ASIC1 and phosphofructokinase muscle-type (PFKM) in liver cancer cell survival. Our results showed that ASIC1 expression was significantly elevated in liver tumor tissues and correlated with tumor progression. Acidic conditions increased ASIC1 expression in both cell lines, enhancing cell survival, while knockdown of ASIC1 reduced viability and increased apoptosis, particularly under acidic conditions. Moreover, PFKM silencing reversed the survival advantage conferred by ASIC1, confirming PFKM as a critical downstream effector. Additionally, lactate dehydrogenase (LDH) and phosphofructokinase (PFK) activity assays showed no significant changes, suggesting other regulatory mechanisms may also be involved. These findings suggest that the ASIC1/PFKM pathway promotes liver cancer cell survival in acidic environments, representing a potential therapeutic target for disrupting tumor adaptation in liver malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.